Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | PRKCG | P05129 | 2/20 | 0.47 |
| ▸ | PRKCB | P05771 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | PRKACG | P22612 | 2/20 | 0.47 |
| ▸ | PRKACB | P22694 | 2/20 | 0.47 |
| ▸ | PRKCH | P24723 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7892632 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Hydrochloric Acid SCHEMBL1429753 | 0.99 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1714375 | 0.85 | L3MBTL1 (0.58) | LMNAACHEMEN1KMT2APRKD3 | |
| SCHEMBL16442259 | 0.85 | L3MBTL1 (0.58) | LMNAACHEMEN1KMT2APRKD3 | |
| SCHEMBL5635569 | 0.85 | L3MBTL1 (0.58) | LMNAACHEMEN1KMT2APRKD3 | |
| SCHEMBL10042202 | 0.83 | MMP1 (0.65) | MAPTLMNASMN1; SMN2TSHRHTT | |
| SCHEMBL10071024 | 0.82 | PRKCD (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6410896 | 0.82 | HSD11B1 (0.48) | LMNAMEN1KMT2APRKD3PRKCG | |
| SCHEMBL7991187 | 0.82 | HSD11B1 (0.48) | LMNAMEN1KMT2APRKD3PRKCG | |
| Hydrochloric Acid SCHEMBL308298 | 0.81 | HSD11B1 (0.47) | LMNAMEN1KMT2APRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8530478-B2 | Piperazine derivatives used as CAV2.2 calcium channel modulators | Convergence Pharmaceuticals Limited (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530478-B2 | Piperazine derivatives used as CAV2.2 calcium channel modulators | Convergence Pharmaceuticals Limited (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2346828-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
| WO-2010102663-A1 | PIPERAZINE DERIVATIVES FOR USE IN THERAPY | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102663-A1 | PIPERAZINE DERIVATIVES FOR USE IN THERAPY | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007072-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | PSEN1 416/4885PSEN2 190/4885APH1B 2083/4885 |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CACNA1B, CACNA1C, CACNB2 | PSEN1 304/4885PSEN2 169/4885APH1B 1601/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | PSEN1 207/4885PSEN2 130/4885APH1B 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.